コンジュゲート・ワクチンの世界市場レポート 2025年

コンジュゲート・ワクチンの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.7％で345億9,000万米ドルに成長します。予測期間の成長は、予防接種政策の拡大、人口の高齢化、新しいワクチンの適応、世界の健康安全保障への懸念、国際協力、経済開発への影響などに起因すると考えられます。予測期間中の主な動向としては、ワクチン流通のための協力やパートナーシップ、高リスク集団に合わせたアプローチ、新興感染症への適用、ワクチン製造技術の進歩、ワクチン公平性のための世界ヘルスイニシアチブなどが挙げられます。

成人の間で結合型ワクチンの使用が増加していることが、コンジュゲート・ワクチン市場の成長を牽引すると予測されます。これらのワクチンは、細菌の莢膜多糖に対する強力な免疫反応を誘発するように設計されており、それによって細菌感染に対する身体の防御を強化します。結合型ワクチンを成人に使用することで、強力な免疫反応を刺激し、重症化、合併症、細菌性疾患のトランスミッションのリスクを下げることができます。例えば、2024年6月、英国を拠点とする公衆衛生機関であるUK Health Security Agency（UKHSA）の報告によると、英国における「6-in-1」ワクチンの12ヵ月間の接種率は91.7％と安定しています。肺炎球菌（PCV）の1回目の接種率は93.7％で、ロタウイルスの接種率は0.6％増加し、89.3％に達しました。さらに、B型髄膜炎ワクチン（MenB2）の2回目の接種率は0.1％上昇し、91.5％となった。このように、成人における結合型ワクチンの使用が増加していることが、コンジュゲート・ワクチン市場の拡大に寄与しています。

感染症の流行増加は、コンジュゲート・ワクチン市場の成長を促進すると予想されます。感染症とは、細菌、ウイルス、寄生虫、真菌などの病原性微生物によって引き起こされる病態のことで、人から人へ、動物から人へ、あるいは環境を介して、直接的または間接的に感染します。結合型ワクチンは、特定の細菌によって引き起こされる感染症、特に乳幼児のような感染しやすい集団の感染症を予防するために不可欠です。例えば、スイスに本部を置く国際的な公衆衛生機関である世界保健機関（WHO）は2023年11月、2022年に世界で約1,060万人が結核と診断され、うち580万人が男性、350万人が女性、130万人が小児であると報告しました。したがって、感染症の発生率の増加がコンジュゲート・ワクチン市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界コンジュゲート・ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のコンジュゲート・ワクチン市場：成長率分析
• 世界のコンジュゲート・ワクチン市場の実績：規模と成長, 2019-2024
• 世界のコンジュゲート・ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界コンジュゲート・ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のコンジュゲート・ワクチン市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一価結合ワクチン
• 多価なコンジュゲート・ワクチン
• 世界のコンジュゲート・ワクチン市場病原体別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌性
• バイラル
• 世界のコンジュゲート・ワクチン市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺炎球菌
• インフルエンザ
• 髄膜炎菌
• 腸チフス
• 世界のコンジュゲート・ワクチン市場患者別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 世界のコンジュゲート・ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア設定
• その他のエンドユーザー
• 世界のコンジュゲート・ワクチン市場一価結合ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単一病原体結合ワクチン
• 世界のコンジュゲート・ワクチン市場多価結合ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多病原体結合ワクチン
• 複合ワクチン

第7章 地域別・国別分析

• 世界のコンジュゲート・ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のコンジュゲート・ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• コンジュゲート・ワクチン市場：競合情勢
• コンジュゲート・ワクチン市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Serum Institute of India Private Limited
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG
• GreenSignal Bio Pharma Limited
• Taj Pharmaceuticals Limited
• Vaxcyte Inc.
• Neuron Biotech Co. Ltd.
• Bio-Med Pvt. Ltd.
• Sinovac Biotech Ltd.
• Takeda Pharmaceutical Company Limited
• Valneva SE
• Dynavax Technologies Corporation
• Emergent BioSolutions Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• コンジュゲート・ワクチン市場2029：新たな機会を提供する国
• コンジュゲート・ワクチン市場2029：新たな機会を提供するセグメント
• コンジュゲート・ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Conjugate vaccines, also referred to as immunogen conjugates, represent advanced immune system modulators extensively employed to induce protection against invading pathogens or stimulate specific antibodies against a targeted molecule. The conjugation process plays a crucial role in augmenting the immune response, enabling a more effective recognition of the pathogen by the immune system.

Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugate vaccine market size has grown rapidly in recent years. It will grow from$18.9 billion in 2024 to $21.46 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to disease burden, government immunization programs, increased awareness, pediatric vaccination emphasis, preventive healthcare trends

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $34.59 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanding immunization policies, aging population dynamics, new vaccine indications, global health security concerns, international collaboration, economic development impact. Major trends in the forecast period include collaborations and partnerships for vaccine distribution, tailored approaches for high-risk populations, application in emerging infectious diseases, advancements in vaccine manufacturing technologies, global health initiatives for vaccine equity.

The rising use of conjugate vaccines among adults is projected to drive the growth of the conjugate vaccine market. These vaccines are designed to elicit a strong immune response against bacterial capsular polysaccharides, thereby enhancing the body's defense against bacterial infections. Utilizing conjugate vaccines in adults can lower the risk of severe illness, complications, and the transmission of bacterial diseases by stimulating a vigorous immune response. For example, in June 2024, reports from the UK Health Security Agency (UKHSA), a public health organization based in the UK, indicated that the 12-month coverage for the '6-in-1' vaccine in the UK remained steady at 91.7%. The first dose of the pneumococcal conjugate vaccine (PCV) was at 93.7%, while rotavirus coverage increased by 0.6%, reaching 89.3%. Additionally, the second dose of the meningitis B vaccine (MenB2) rose by 0.1% to 91.5%. Thus, the growing use of conjugate vaccines in adults is contributing to the expansion of the conjugate vaccine market.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the conjugate vaccine market. Infectious diseases are conditions caused by pathogenic microorganisms, including bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly from person to person, from animals to humans, or through environmental sources. Conjugate vaccines are essential in preventing infectious diseases caused by specific bacteria, particularly among vulnerable populations such as infants and young children. For example, in November 2023, the World Health Organization (WHO), an international public health agency based in Switzerland, reported that approximately 10.6 million individuals worldwide were diagnosed with tuberculosis (TB) in 2022, including 5.8 million men, 3.5 million women, and 1.3 million children. Therefore, the rising incidence of infectious diseases is fueling the expansion of the conjugate vaccine market.

Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.

Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.

In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Conjugate Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The conjugate vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
• 2) By Pathogen: Bacterial; Viral
• 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
• 4) By Patient: Pediatric; Adults
• 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
• Subsegments:
• 1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
• 2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines; Combination Conjugate Vaccines
• Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Conjugate Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Conjugate Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Conjugate Vaccine Market Growth Rate Analysis
• 5.4. Global Conjugate Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Conjugate Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Conjugate Vaccine Total Addressable Market (TAM)

6. Conjugate Vaccine Market Segmentation

• 6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccine
• 6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial
• Viral
• 6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal
• Influenza
• Meningococcal
• Typhoid
• 6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adults
• 6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• Other End Users
• 6.6. Global Conjugate Vaccine Market, Sub-Segmentation Of Monovalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Pathogen Conjugate Vaccines
• 6.7. Global Conjugate Vaccine Market, Sub-Segmentation Of Multivalent Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Pathogen Conjugate Vaccines
• Combination Conjugate Vaccines

7. Conjugate Vaccine Market Regional And Country Analysis

• 7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

• 8.1. Asia-Pacific Conjugate Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Conjugate Vaccine Market

• 9.1. China Conjugate Vaccine Market Overview
• 9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Conjugate Vaccine Market

• 10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Conjugate Vaccine Market

• 11.1. Japan Conjugate Vaccine Market Overview
• 11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Conjugate Vaccine Market

• 12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Conjugate Vaccine Market

• 13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Conjugate Vaccine Market

• 14.1. South Korea Conjugate Vaccine Market Overview
• 14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Conjugate Vaccine Market

• 15.1. Western Europe Conjugate Vaccine Market Overview
• 15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Conjugate Vaccine Market

• 16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Conjugate Vaccine Market

• 17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Conjugate Vaccine Market

• 18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Conjugate Vaccine Market

• 19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Conjugate Vaccine Market

• 20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Conjugate Vaccine Market

• 21.1. Eastern Europe Conjugate Vaccine Market Overview
• 21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Conjugate Vaccine Market

• 22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Conjugate Vaccine Market

• 23.1. North America Conjugate Vaccine Market Overview
• 23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Conjugate Vaccine Market

• 24.1. USA Conjugate Vaccine Market Overview
• 24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Conjugate Vaccine Market

• 25.1. Canada Conjugate Vaccine Market Overview
• 25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Conjugate Vaccine Market

• 26.1. South America Conjugate Vaccine Market Overview
• 26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Conjugate Vaccine Market

• 27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Conjugate Vaccine Market

• 28.1. Middle East Conjugate Vaccine Market Overview
• 28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Conjugate Vaccine Market

• 29.1. Africa Conjugate Vaccine Market Overview
• 29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Conjugate Vaccine Market Competitive Landscape
• 30.2. Conjugate Vaccine Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bharat Biotech International Limited Overview, Products and Services, Strategy and Financial Analysis

31. Conjugate Vaccine Market Other Major And Innovative Companies

• 31.1. Serum Institute of India Private Limited
• 31.2. Biological E. Limited
• 31.3. Bavarian Nordic A/S
• 31.4. CSL Limited
• 31.5. Novartis AG
• 31.6. GreenSignal Bio Pharma Limited
• 31.7. Taj Pharmaceuticals Limited
• 31.8. Vaxcyte Inc.
• 31.9. Neuron Biotech Co. Ltd.
• 31.10. Bio-Med Pvt. Ltd.
• 31.11. Sinovac Biotech Ltd.
• 31.12. Takeda Pharmaceutical Company Limited
• 31.13. Valneva SE
• 31.14. Dynavax Technologies Corporation
• 31.15. Emergent BioSolutions Inc.

32. Global Conjugate Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Recent Developments In The Conjugate Vaccine Market

35. Conjugate Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Conjugate Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Conjugate Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Conjugate Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer